Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Travoprost (Travatan®) is recommended as an option for use within NHS Wales for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma. |
|||
|
|||
Medicine details |
|||
| Medicine name | travoprost (Travatan®) | ||
| Formulation | 40 micrograms/ml eye drops | ||
| Reference number | 2601 | ||
| Indication | Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma |
||
| Company | Alcon Laboratories (UK) Ltd | ||
| BNF chapter | Eye | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 3115 | ||
| NMG meeting date | 09/09/2015 | ||
| AWMSG meeting date | 21/10/2015 | ||
| Ratification by Welsh Government | 17/11/2015 | ||
| Date of issue | 18/11/2015 | ||
| Date of last review | 20/03/2019 | ||